Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS P...
Highlights: * FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS P...
Highlights: * U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational ther...
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global lic...
Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuropr...
Highlights: * IND application submission to the U.S. Food and Drug Administration (FDA) is a piv...
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotro...
Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan ...
MELBOURNE, Australia, Oct. 15, 2024 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ) ("Neur...